
Quotient Limited QTNT
Quarterly report 2022-Q4
added 02-09-2023
Quotient Limited Interest Expense 2011-2026 | QTNT
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Quotient Limited
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 2.72 M | 2.2 M | -6.94 M | 2.37 M | -1.11 M | 3.5 M | -4.06 M | -197 K | 11 K | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.5 M | -6.94 M | -167 K |
Quarterly Interest Expense Quotient Limited
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 20.6 M | 1.01 M | -19.6 M | - | -3.51 M | 677 K | 4.18 M | 9.5 M | 617 K | 192 K | 5 M | 233 K | 1.89 M | 1.89 M | -1.24 M | 952 K | -1.54 M | -1.54 M | -468 K | - | 33 K | 565 K | 880 K | - | -4.57 M | -1.89 M | 2.68 M | - | 305 K | -987 K | -1.29 M | - | 130 K | -1.49 M | 534 K | - | -45 K | -83 K | 77 K | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 20.6 M | -19.6 M | 416 K |
Interest Expense of other stocks in the Diagnostics research industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Castle Biosciences
CSTL
|
144 K | $ 20.26 | -18.14 % | $ 587 M | ||
|
Centogene N.V.
CNTG
|
8.42 M | - | -6.23 % | $ 30.6 M | ||
|
Burning Rock Biotech Limited
BNR
|
1.54 M | $ 17.17 | 0.94 % | $ 179 M | ||
|
Agilent Technologies
A
|
81 M | $ 118.38 | 0.51 % | $ 36 B | ||
|
Akumin
AKU
|
118 M | - | -17.87 % | $ 25.9 M | ||
|
Aspira Women's Health
AWH
|
1.81 M | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
235 K | - | -61.36 % | $ 2.46 M | ||
|
Biocept
BIOC
|
316 K | - | -13.05 % | $ 7.29 M | ||
|
CareDx, Inc
CDNA
|
524 K | $ 21.85 | 4.3 % | $ 1.16 B | ||
|
Chembio Diagnostics
CEMI
|
2.94 K | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
13 K | - | - | $ 9.42 M | ||
|
HTG Molecular Diagnostics
HTGM
|
857 K | - | -20.0 % | $ 1.06 M | ||
|
Co-Diagnostics
CODX
|
106 K | $ 1.69 | 3.05 % | $ 2.25 M | ||
|
Medpace Holdings
MEDP
|
-5.34 M | $ 428.22 | 0.34 % | $ 12.4 B | ||
|
Global Cord Blood Corporation
CO
|
6.27 M | - | - | $ 399 M | ||
|
Genetic Technologies Limited
GENE
|
15.2 K | - | - | $ 7.1 B | ||
|
Myriad Genetics
MYGN
|
800 K | $ 4.13 | 0.47 % | $ 382 M | ||
|
DermTech
DMTK
|
-355 K | - | -11.32 % | $ 2.94 M | ||
|
Charles River Laboratories International
CRL
|
-22.6 M | $ 184.63 | 1.6 % | $ 9.15 B | ||
|
NeoGenomics
NEO
|
296 K | $ 9.05 | 1.8 % | $ 1.16 B | ||
|
Enzo Biochem
ENZ
|
494 K | - | -8.98 % | $ 14.8 K | ||
|
National Research Corporation
NRC
|
-95 K | $ 17.84 | -0.11 % | $ 399 M | ||
|
Natera
NTRA
|
9.32 M | $ 216.42 | 0.62 % | $ 21.3 B | ||
|
Exact Sciences Corporation
EXAS
|
18.6 M | - | - | $ 19.8 B | ||
|
Fulgent Genetics
FLGT
|
561 K | $ 15.01 | 0.6 % | $ 454 M | ||
|
Koninklijke Philips N.V.
PHG
|
288 M | $ 27.48 | 1.03 % | $ 26.1 B | ||
|
Personalis
PSNL
|
24 K | $ 6.1 | 0.43 % | $ 361 M | ||
|
Guardant Health
GH
|
-10.5 M | $ 90.2 | -2.22 % | $ 11.3 B | ||
|
Soleno Therapeutics
SLNO
|
110 K | $ 52.93 | -0.02 % | $ 2.69 B | ||
|
Heska Corporation
HSKA
|
4.19 M | - | - | $ 1.31 B | ||
|
ICON Public Limited Company
ICLR
|
337 M | $ 124.86 | 0.59 % | $ 10.3 B | ||
|
Illumina
ILMN
|
-292 M | $ 139.58 | -2.1 % | $ 22.2 B | ||
|
Senseonics Holdings
SENS
|
-23 K | $ 5.28 | -1.49 % | $ 220 M | ||
|
Interpace Biosciences
IDXG
|
-252 K | $ 2.04 | -3.33 % | $ 9.02 M | ||
|
QIAGEN N.V.
QGEN
|
-6.65 M | - | - | $ 10.6 B | ||
|
Biomerica
BMRA
|
367 | $ 2.17 | -1.84 % | $ 4.98 M | ||
|
Trinity Biotech plc
TRIB
|
6.75 M | $ 0.61 | 0.17 % | $ 219 M | ||
|
Thermo Fisher Scientific
TMO
|
-12 M | $ 473.58 | 0.05 % | $ 179 B | ||
|
Lantheus Holdings
LNTH
|
31.3 M | $ 89.94 | 4.4 % | $ 6.07 B | ||
|
Laboratory Corporation of America Holdings
LH
|
224 M | $ 256.77 | -0.07 % | $ 21.4 B | ||
|
Twist Bioscience Corporation
TWST
|
-903 K | $ 58.84 | -1.16 % | $ 3.52 B | ||
|
Celcuity
CELC
|
2.11 M | $ 129.8 | -6.91 % | $ 6.07 B | ||
|
Motus GI Holdings
MOTS
|
211 | - | -34.28 % | $ 263 K | ||
|
Neogen Corporation
NEOG
|
38.1 M | $ 9.18 | -0.05 % | $ 1.99 B | ||
|
Quest Diagnostics Incorporated
DGX
|
26 M | $ 189.68 | 0.29 % | $ 21.1 B | ||
|
Waters Corporation
WAT
|
14.3 M | $ 345.28 | -1.3 % | $ 20.6 B |